Clinical, Functional, and Radiographic Implications of Time to Treatment Response in Patients With Early Rheumatoid Arthritis: a Posthoc Analysis of the PREMIER Study

@article{Keystone2014ClinicalFA,
  title={Clinical, Functional, and Radiographic Implications of Time to Treatment Response in Patients With Early Rheumatoid Arthritis: a Posthoc Analysis of the PREMIER Study},
  author={Edward C Keystone and Boulos Haraoui and Benoǐt Gu{\'e}rette and Neelufar Mozaffarian and Shufang Liu and Arthur Kavanaugh},
  journal={The Journal of Rheumatology},
  year={2014},
  volume={41},
  pages={235 - 243}
}
Objective. Rheumatoid arthritis (RA) treatment recommendations suggest target attainment within the first 3 months of therapy, yet delayed clinical responses can occur. This analysis assessed the longterm clinical, functional, and radiographic outcomes associated with delayed responses to methotrexate (MTX) monotherapy or to the combination of adalimumab (ADA) + MTX. Methods. In this posthoc analysis, patients with early RA who received MTX monotherapy or ADA + MTX in the PREMIER study were… 
View on Publisher
jrheum.org
19 Citations
Background Citations
5
Methods Citations
2

Figures, Tables, and Topics from this paper

19 Citations

Citation Type

Citation Type

Prognostic Factors Toward Clinically Relevant Radiographic Progression in Patients With Rheumatoid Arthritis in Clinical Practice
TLDR
The subgroup analysis revealed that time-integrated DAS28-ESR is not a predictor whereas the introduction of bDMARDs is a significant protective factor for CRRP in RA patients with disease duration <3 years.
Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis
TLDR
Switching from MTX monotherapy to combination therapy with either an originator biologic or biosimilar TNFis at 6 months after csDMARD failure in patients with RA was cost-effective at a threshold of £30,000/QALY.
Rheumatoid arthritis treatment: the earlier the better to prevent joint damage
TLDR
In this short review, the available evidence supporting the value of treating rheumatoid arthritis early and the impact on disease outcomes is analysed, with particular focus on radiographic progression.
Are prognostic factors adequately selected to guide treatment decisions in patients with rheumatoid arthritis? A collaborative analysis from three observational cohorts.
Predictors of Remission Maintenance after Etanercept Tapering or Withdrawal in Early Rheumatoid Arthritis: Results from the PRIZE Study
TLDR
Fast response and suppression of inflammation with etanercept-methotrexate therapy may predict successful etanenercept tapering/withdrawal in patients with early rheumatoid arthritis.
Magnetic Resonance Imaging Bone Edema at Enrollment Predicts Rapid Radiographic Progression in Patients with Early RA: Results from the Nagasaki University Early Arthritis Cohort
TLDR
MRI bone edema is closely associated with the development of RRP in patients with early-stage rheumatoid arthritis, and Physicians should carefully control the disease activity when MRI bone Edema is observed in patientswith early RA.
Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies
TLDR
Prognostic factors in rheumatoid arthritis are defined heterogeneously and the relevance of a single or combined presence of poor prognostic factors remains unclear.
Change of ARASHI scores for large joints in rheumatoid arthritis patients treated with abatacept for three years: A clinical observational study
TLDR
The greatest suppression of the radiographic progressive damage of large joints was achieved for the shoulders and knees, and ankle joint damage should be monitored even in patients treated with abatacept.
Rheumatoid Arthritis: Common Questions About Diagnosis and Management.
TLDR
In a patient with inflammatory arthritis, the presence of a rheumatoid factor and/or anti-citrullinated protein antibody, elevated C-reactive protein level, or elevated erythrocyte sedimentation rate is consistent with a diagnosis of r heumatoid arthritis.
Clinical Manifestations and Myositis-Specific Autoantibodies Associated with Physical Dysfunction after Treatment in Polymyositis and Dermatomyositis: An Observational Study of Physical Dysfunction with Myositis in Japan
TLDR
Age at disease onset, gender, CK level before treatment, and anti-SRP were significant predictors associated with physical dysfunction after treatment in PM/DM.
...
1
2
...

References

SHOWING 1-10 OF 44 REFERENCES
Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
TLDR
Even in patients without clinical improvement, treatment with infliximab plus MTX provided significant benefit with regard to the destructive process, suggesting that in such patients these 2 measures of disease are dissociated.
Rapid Improvement in the Signs and Symptoms of Rheumatoid Arthritis Following Certolizumab Pegol Treatment Predicts Better Longterm Outcomes: Post-hoc Analysis of a Randomized Controlled Trial
TLDR
Analysis of the kinetics of response to CZP during the first 12 weeks of therapy potentially permits informed prediction of clinical success or need to alter treatment.
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
TLDR
In patients with early RA, initial combination therapy including either prednisone or infliximab resulted in earlier functional improvement and less radiographic damage after 1 year than did sequential monotherapy or step-up combination therapy.
Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients.
TLDR
The findings indicate that intensive and dynamic treatment strategies that include a closer look at disease activity at 3 months in patients with early and late RA is warranted, and patients who reach a moderate or low disease activity status after 3-6 months of therapy may require switching to alternative therapies.
Less Radiographic Progression with Adalimumab Plus Methotrexate Versus Methotrexate Monotherapy Across the Spectrum of Clinical Response in Early Rheumatoid Arthritis
TLDR
In patients with early RA, adalimumab plus MTX resulted in less radiographic progression than MTX monotherapy across the spectrum of clinical response, including ACR20 non-responses and remission-like responses.
Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial.
TLDR
High CRP level, high ESR, or persistent disease activity was associated with greater radiographic progression in the group taking MTX alone, while little radiography progression was seen in patients receiving both MTX and infliximab, regardless of the abnormal levels of these traditional predictors.
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade
TLDR
With methotrexate, joint damage progresses even at low and moderate disease activity levels, whereas methotRexate plus infliximab inhibits radiographic progression across all disease activity states, according to a direct relationship between disease activity and radiographic changes.
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
TLDR
In this 52-week trial, adalimumab was more effective than placebo at inhibiting the progression of structural joint damage, reducing the signs and symptoms, and improving physical function in patients with active RA who had demonstrated an incomplete response to MTX.
Factors Associated with Radiographic Progression in Patients with Rheumatoid Arthritis Who Were Treated with Methotrexate
TLDR
In patients with RA, measures of CRP and SJC after 12 weeks of MTX therapy emerged as the factors most associated with radiographic progression at Week 52.
Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
TLDR
Older age, low functional status, and concomitant prednisolone treatment were negative predictors of a clinical response and remission in patients with rheumatoid arthritis.
...
1
2
3
4
5
...